We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Sanofi has secured the US Food and Drug Administration (FDA) Breakthrough Therapy designation for Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in patients aged 12 years and older.
US-based pharmaceutical firm Gilead Sciences has agreed to acquire Immunomedics, a developer of antibody-drug conjugates (ADC) platform, for $21bn. Under the terms of the transaction, Gilead will place
AstraZeneca has resumed the clinical trial programme of its Covid-19 vaccine AZD1222 in the UK, after the vaccine’s safety being confirmed by the Medicines Health Regulatory Authority (MHRA).
Johnson & Johnson (J&J) pharmaceutical business Janssen has applied with the US Food and Drug Administration (FDA) for the approval of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat
Roche has unveiled new data from analyses, showing its ENSPRYNG (satralizumab) reduces severity and risk of relapse in the treatment of neuromyelitis optica spectrum disorder (NMOSD). The post-hoc
GlaxoSmithKline (GSK) has received an expanded US Food and Drug Administration (FDA) approval for its Trelegy Ellipta to treat asthma and chronic obstructive pulmonary disease (COPD). Trelegy Ellipta
The French Competition Authority has reportedly charged pharmaceutical companies Roche and Novartis, with a €444m fine for abusive practices related to Lucentis injection for age-related macular degeneration (AMD).
Japanese pharmaceutical company Takeda has agreed to sell its portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm. Germany-based speciality pharmaceutical company
AstraZeneca has reportedly stopped its global Phase 3 clinical trial of its investigational Covid-19 vaccine AZD1222, following an unexplained illness observed in a participant. The UK-based drugmaker said
Pfizer and BioNTech have secured the German regulatory approval to begin the Phase 2/3 clinical trial of their potential Covid-19 vaccine candidate BNT162b2. The German regulatory authority Paul-Ehrlich-Institut